

1 **Human thymopoiesis selects unconventional CD8<sup>+</sup>  $\alpha/\beta$  T cells that respond to multiple**  
2 **viruses.**

3

4 Valentin Quiniou<sup>1,2</sup>, Pierre Barennes<sup>1,2</sup>, Federica Martina<sup>2#</sup>, Vanessa Mhanna<sup>1#</sup>, Helene  
5 Vantomme<sup>1,2#</sup>, Hang Phuong Pham<sup>3</sup>, Mikhail Shugay<sup>4</sup>, Adrien Six<sup>1</sup>, Encarnita Mariotti-  
6 Ferrandiz<sup>1,2</sup>, David Klatzmann<sup>1,2\*</sup>

7

8 <sup>1</sup>Sorbonne Université, INSERM, Immunology-Immunopathology-Immunotherapy (i3), Paris,  
9 France

10 <sup>2</sup>AP-HP, Hôpital Pitié-Salpêtrière, Clinical Investigation Center for Biotherapies (CIC-BTi) and  
11 Immunology-Inflammation-Infectiology and Dermatology Department (3iD), Paris, France

12 <sup>3</sup>ILTOO pharma, Statistical department, Paris, France

13 <sup>4</sup>Center of Life Sciences, Skoltech, Moscow, Russia

14 # these authors have contributed equally

15

16 \* Address correspondence and reprint requests to:

17 Prof. D. Klatzmann, Pitié-Salpêtrière Hospital, 83 boulevard de l'Hôpital, F-75013, Paris, France.

18 E-mail: david.klatzmann@sorbonne-universite.fr

19 T cell receptors (TCRs) are formed by stochastic gene rearrangements, theoretically generating  
20  $>>10^{19}$  sequences<sup>1</sup>. They are selected during thymopoiesis, which releases a repertoire of  
21 about  $10^8$  unique TCRs<sup>2,3</sup> per individual. How evolution shaped a process that produces TCRs  
22 that would effectively respond to infectious agents is a central question of immunology. The  
23 paradigm is that a diverse enough repertoire of TCRs should always provide a proper, though  
24 rare, specificity for any given need. Expansion of such rare T cells would provide enough fighters  
25 for an efficacious immune response and enough antigen-experienced cells for memory<sup>3,4</sup>. We  
26 show here that thymopoiesis releases a large population of CD8<sup>+</sup> T cells harbouring diverse  
27  $\alpha/\beta$ TCRs with innate-like properties. These TCRs (i) have high generation probabilities and a  
28 preferential usage of some V and J genes, (ii) are shared between individuals, (iii) are highly  
29 enriched for viral antigen recognition and (iv) have a fuzzy rather than tight specificity. In vitro,  
30 T cells expressing these TCRs bind to and are activated by multiple unrelated viral peptides; in  
31 vivo, they respond to vaccination and infection, being notably found in bronchoalveolar lavages  
32 of COVID-19 infected patients. Our results support an evolutionary selection of pleiospecific  
33  $\alpha/\beta$ TCRs for broad antiviral responses and heterologous immunity.


34

35 We analysed the TCR repertoire dynamics of developing thymocytes. We first focused  
36 on the hypervariable CDR3 region of the TCR that interacts with the antigenic peptide, while  
37 CDR1 and CDR2 usually interact with HLA molecules<sup>5</sup>. CDR3 analyses can therefore be used to  
38 investigate the sharing of TCR specificities between individuals with distinct HLA molecules. We  
39 analysed the repertoire of purified CD4<sup>+</sup>CD8<sup>+</sup>CD3<sup>-</sup> (DPCD3<sup>-</sup>), CD4<sup>+</sup>CD8<sup>+</sup>CD3<sup>+</sup> (DPCD3<sup>+</sup>) and CD4<sup>-</sup>  
40 CD8<sup>+</sup>CD3<sup>+</sup> (CD8<sup>+</sup>) thymocytes. DPCD3<sup>-</sup> thymocytes represent the earliest stage of TCR  $\beta$ -chain  
41 gene recombination and their repertoire embodies the unaltered outcome of the TCR  
42 generation process; DPCD3<sup>+</sup> thymocytes are at an early stage of the selection process and their  
43 repertoire should be minimally modified; CD8<sup>+</sup> thymocytes have passed the selection process  
44 and bear a fully selected repertoire. We analysed and represented the structure of these  
45 repertoires by connecting CDR3s (nodes) differing by at most one single amino acid (AA)  
46 (Levenshtein distance less than or equal to one: LD $\leq$ 1) as such similar CDR3s most often bind  
47 the same peptide<sup>6-12</sup> (Supplementary Figure 1. In these networks, connected CDR3s are  
48 designated as clustered nodes and the others as dispersed nodes. For normalisation, we  
49 represented the first 18,000 most expressed  $\beta$  or  $\alpha$  CDR3s from each sample. We observed a  
50 marked increase in the number of clustered CDR3s from DPCD3<sup>-</sup> to CD8<sup>+</sup> thymocytes (Fig. 1a  
51 and c, Supplementary Figure 2), which was remarkably consistent among all individuals studied,  
52 independently of their age, sex or HLA (Supplementary Figure 3). The node degree, i.e. its  
53 number of connections, was also significantly increased during T cell differentiation for  
54 clustered CDR3s (Fig. 1b and d, Supplementary Figure 2). The major and statistically significant  
55 ( $p < 0.0001$ ) increase in the proportion of clustered TCRs from DPCD3<sup>+</sup> to CD8<sup>+</sup> thymocytes,  
56 which was also accompanied by a significant increase ( $p < 0.0001$ ) in the node degree of  
57 clustered TCRs, reveals a positive selection of TCRs with shared recognition properties during  
58 thymopoiesis.

59 The probability of generation ( $P_{gen}$ ) of a given TCR varies enormously from one TCR to  
60 the other, spanning over 10 orders of magnitude<sup>1</sup>. The clustered TCRs from both DPCD3<sup>+</sup> and  
61 CD8<sup>+</sup> thymocytes have a significantly higher  $P_{gen}$  ( $p < 0.0001$ ) than the dispersed ones (Fig. 1e).  
62  $P_{gen}$  also increased significantly ( $p < 0.0001$ ) from DPCD3<sup>+</sup> to CD8<sup>+</sup> thymocytes (Fig. 1e).  
63 Moreover, the  $P_{gen}$  of CD8<sup>+</sup> thymocytes is significantly correlated with the node degree  
64 (Supplementary Figure 4). Clustered TCRs have a preferential usage of some V and J genes,  
65 resulting in a markedly different VJ recombination usage, notably similar across individuals (Fig.  
66 1f, Supplementary Figure 5). As there is a remarkably shared clustered structure of CD8<sup>+</sup>

67 thymocytes  $\beta$ CDR3s across individuals (Supplementary Figure 3), we investigated their private  
68 or public nature (Fig. 1g, Supplementary table 1). We found a significant increase of public (i.e.  
69 shared between at least 2 individuals)  $\beta$ CDR3s in  $CD8^+$  versus  $DPCD3^+$  thymocytes, which is  
70 mostly that of the clustered  $\beta$ CDR3s. For  $CD8^+$  thymocytes, up to 31.7% of clustered  $\beta$ CDR3s  
71 are public compared to barely 1% of the dispersed ones (Fig. 1g, Supplementary Figure 6).  
72 These results are independent of HLA alleles sharing (Supplementary Figure 7). The  $\beta$ CDR3s  
73 with the highest *Pgen* values and degree were the most shared between individuals  
74 (Supplementary Figure 8). Moreover, there is a convergence of specificities between  
75 individuals' repertoires, as many  $\beta$ CDR3s of one individual are connected to those of other  
76 individuals (up to twelve), and more frequently in  $CD8^+$  versus  $DPCD3^+$  thymocytes  
77 (Supplementary Figure 9). Altogether, these results indicate that the mechanisms for TCR  
78 generation and for their further thymic selection are biased to shape a public repertoire of  
79 connected  $\beta$ CDR3s with shared recognition properties.  
80






81  
82  
83  
84  
85  
86  
87  
88  
89  
90

**Figure 1. Thymocyte differentiation produces clustered and public CDR3s with high generation probability.** Representations and analysis are performed on the first 18,000 most frequent  $\beta$ CDR3s. **a.** Representation of  $\beta$ CDR3 LD $\leq 1$  networks from DPCD3<sup>-</sup>, DPCD3<sup>+</sup> and CD8<sup>+</sup> thymocytes for one representative donor. Each node represents a single  $\beta$ CDR3. **b.** Node degree (number of connections) of clustered  $\beta$ CDR3 for DPCD3<sup>+</sup> and CD8<sup>+</sup> thymocytes from 6 donors (P11 to P25). Each node represents a single  $\beta$ CDR3, the colour of which represents its degree (log scale). **c-e.** Data are mean $\pm$ s.e.m. from two DPCD3<sup>-</sup>, ten DPCD3<sup>+</sup> and twelve CD8<sup>+</sup> thymocyte samples; **c.** Percentage of clustered  $\beta$ CDR3s (\* $p=0.0152$  and \*\*\*\* $p<0.0001$ , Mann-Whitney test); **d.** Node degree for clustered  $\beta$ CDR3s

91 (\*\*\*\* $p < 0.0001$ , Mann-Whitney test); **e.** Generation probability (*Pgen*) of dispersed and clustered  
92  $\beta$ CDR3s (\*\*\*\* $p < 0.0001$ , Mann-Whitney test). **f.** PCA analysis of TRB VJ gene combinations in CD8  
93 thymocytes. Blue: dispersed nodes; Red: clustered nodes. **g.** Mean percentages of public (black) or  
94 private (grey)  $\beta$ CDR3s in all, dispersed or clustered nodes. (\*\*\*\* $p < 0.0001$ , Mann-Whitney test).

95  
96 The preferential selection of clustered public TCRs that could represent over 8% of the  
97 sampled repertoire (Fig. 1g) raises the question of their specificities<sup>13</sup>. As the main function of  
98 CD8<sup>+</sup> T cells is cytotoxicity towards virally infected cells, we investigated whether the clustered  
99 TCRs could be associated with virus recognition. We curated databases of  $\beta$ CDR3s specific for  
100 human infectious pathogens<sup>14,15</sup> to retain only those 5,437 that had been identified by  
101 tetramer-based selection, i.e. binding to a soluble HLA bound to a defined peptide. We  
102 detected an enrichment of these  $\beta$ CDR3s in CD8<sup>+</sup> versus DP3CD3<sup>+</sup> thymocytes ( $p < 0.0001$ ) and in  
103 clustered versus dispersed CD8<sup>+</sup> thymocytes ( $p < 0.0001$ ) (Fig. 2a and b, Supplementary Figure  
104 10. , Supplementary table 2). Moreover, these virus-specific  $\beta$ CDR3s were significantly enriched  
105 within  $\beta$ CDR3s with the highest *Pgen* and node degree (Fig. 2c, Supplementary Figure 11. ) and  
106 were highly shared between individuals (Fig. 2d).

107 We aimed to confirm these observations with virus-specific paired  $\alpha$  and  $\beta$  TCR chains  
108 obtained from single-cell TCR sequencing. These sequences were obtained from 160,914 blood  
109 CD8<sup>+</sup> T cells isolated from four healthy donors and incubated simultaneously with barcoded  
110 dextramers complexed with peptides from CMV, EBV, HIV, HPV, HTLV and influenza<sup>16</sup>. We  
111 observed a significant increase in the representation of the virus-specific  $\alpha$  and  $\beta$  TCR chains in  
112 CD8<sup>+</sup> versus DP3CD3<sup>+</sup> thymocytes (Fig. 2e and f), with a higher representation of the virus-  
113 specific alpha chains than that of the beta chains. Noteworthy, these TCRs are also mostly  
114 represented in clustered rather than dispersed TCRs from CD8<sup>+</sup> thymocytes (Fig. 2g,  
115 Supplementary table 3). Altogether, these results indicate that the selection of clustered TCRs  
116 with high generation probabilities corresponds, at least in part, to the selection of virus-  
117 associated TCRs whose CDR3s are remarkably conserved between individuals independently of  
118 their HLA.



119

120

**Figure 2. Clustered public TCRs are enriched for virus-specific TCRs.**

121

**a-d.** Analyses of virus-specific  $\beta$ CDR3s from public databases<sup>14,15</sup>.

122

**a.** Mean percentages of virus-specific  $\beta$ CDR3s in DPCD3<sup>+</sup> (n=10) vs CD8<sup>+</sup> (n=12) thymocytes (\*\*\*\*p<0.0001, Mann-Whitney test, mean  $\pm$  s.e.m.).

123

**b.** Virus-specific  $\beta$ CDR3 enrichment in clustered vs dispersed nodes in CD8<sup>+</sup> thymocytes from one representative donor (p<0.0001; Chi-square test). Data for all CD8<sup>+</sup> thymocytes are in

124

Supplementary table 2. **c.** Mean generation probability of virus-specific  $\beta$ CDR3s in dispersed and

125

clustered DPCD3<sup>+</sup> or CD8<sup>+</sup> thymocytes (\*\*\*\*p<0.0001, Mann-Whitney test, mean  $\pm$  s.e.m.). **d.** Sharing of

126

virus-specific  $\beta$ CDR3s in CD8<sup>+</sup> thymocytes. Pie charts represent the  $\beta$ CDR3s from private (1) to shared

127

by all donors (12), in grey for  $\beta$ CDR3s with unknown specificity or in red for those with a virus specificity.

128

**e-g.** Identification of virus-specific TCRs from single-cell sequencing dataset<sup>16</sup>. **e.** Mean percentages of

129

virus-specific  $\alpha$ CDR3s (\*p=0.0496, Mann-Whitney test, mean  $\pm$  s.e.m.). **f.** Mean percentages of virus-

130

specific  $\beta$ CDR3s (\*\*\*\*p<0.0001, Mann-Whitney test, mean  $\pm$  s.e.m.). **g.** Overlay of the  $\beta$ CDR3 network


131

132 of CD8<sup>+</sup> thymocytes from one individual with virus-specific  $\beta$ CDR3s identified in single-cell sequencing  
133 datasets<sup>16</sup>.  
134

135 Intriguingly, we noted that TCRs with different assigned specificities could be detected  
136 within close proximity in single clusters (Supplementary Figure 12), although this should  
137 suggest similar specificities<sup>6-12</sup> (Supplementary Figure 1. ). We thus investigated this  
138 observation in greater detail, at the single-cell level<sup>16</sup>. We first analysed the different TCRs  
139 assigned to recognise EBV peptides, i.e. binding dextramers (Dex<sup>+</sup>) matching the HLA of a given  
140 individual loaded with EBV peptides (Fig. 3a). Single TCRs were found to bind multiple  
141 dextramers loaded with distinct peptides from EBV (Fig. 3b) and some TCRs also bound  
142 dextramers loaded with peptides from unrelated viruses such as CMV, HIV, HPV, HTLV-1 or  
143 influenza (Fig. 3c); TCRs able to bind dextramers specific for both EBV and CMV were even  
144 found in a CMV and EBV seronegative patient (Supplementary Figure 13). TCRs binding multiple  
145 viral peptides have binding scores for the different viral peptides that are highly positively  
146 correlated (Fig. 3d); for example, the different TCRs that bind a dextramer expressing the  
147 “IPSINVHHY” CMV peptide have a strong positive correlation (blue dot) for the binding of a  
148 dextramer expressing the “YLLEMLWRL” EBV peptide (Fig. 3d; red arrows), indicating that most  
149 of the TCRs that bind one of these peptides have an equivalent binding score for the other.  
150 Noteworthy, there is only rare negative correlation (red dots) for the binding of dextramer  
151 harbouring different peptides.

152 We also analysed the binding of HLA-mismatched dextramers. When HLA-mismatch  
153 EBV Dex<sup>+</sup> cells are overlaid on a TSNE representation based on single-cell specificity (Fig. 3e),  
154 some of them corresponded to cells also labelled by HLA-matched EBV dextramers (Fig. 3a),  
155 while some others did not (Fig. 3e, red arrow). As for the HLA-matched dextramers, single TCRs  
156 were found to bind HLA-mismatched dextramers loaded with distinct unrelated peptides from  
157 EBV (Fig. 3f) and some TCRs even bound HLA-mismatched dextramers loaded with epitopes  
158 from different viruses such as CMV, HIV, HPV, HTLV-1 or influenza (Fig. 3g). There were also  
159 mostly positive correlations for the binding to different HLA-mismatched dextramer  
160 specificities (Fig. 3h). Altogether, within a dataset of >160,000 single CD8<sup>+</sup> T cells, among the  
161 66,191 that did bind dextramers, 24,083 could bind more than one viral-derived peptide from  
162 either the same or different viruses, and presented by HLA-matched or even HLA-mismatched  
163 dextramers. Thus, there are pleiospecific CD8<sup>+</sup> T cells (psT cells) whose TCRs are diverse and

164 bind HLA class-I based dextramers, but are not strictly constrained by HLA matching and the  
 165 presented peptide. Such binding properties markedly differ from the classical cross-reactivity  
 166 of TCRs for mimotopes<sup>17</sup> and from those of innate-like MAIT and NKT cells<sup>18,19</sup>. The latter have  
 167 a restricted diversity, with an invariant TCR $\alpha$  chain and a constrained TCR $\beta$  repertoire, and are  
 168 MR1- or CD1-restricted, respectively<sup>18,19</sup>.



169

170



171 **Figure 3. Innate-like TCR binding properties.**


172 **a.** TSNE representation of the single-cell TCR specificities from one individual. HLA-matched EBV-Dex<sup>+</sup>  
173 cells are in blue. **b.** Chord diagram showing TCR binding to multiple HLA-matched EBV Dextramers  
174 loaded with different peptides. Each segment represents TCR binding to the peptides marked above.  
175 The size of the segments corresponds to the number of TCRs binding to these peptides. The link  
176 between segments identifies multiple TCR binding to different peptides. **c.** Chord diagram showing TCR  
177 binding to HLA-matched dextramers loaded with peptides from unrelated viruses. The colours of the  
178 segments represent the different viruses: CMV (red), EBV (green), HIV (dark blue), HPV (light green),  
179 HTLV (purple) and influenza (dark grey). The same colour code is used in d, g and h. The full list of the  
180 different peptides is in Supplementary table 4. **d.** Correlation between the binding scores for the  
181 different HLA-matched virus-specific dextramers from 2 patients. Significant correlations (p-value <  
182 0.01, Pearson correlation) are represented by coloured circles. The intensity of the colours and the size  
183 of the circles are proportional to the correlation coefficients. Positive correlations are displayed in blue  
184 and negative correlations in red. **e.** TSNE representation of the single-cell TCR specificities from one  
185 individual. HLA-mismatched EBV-Dex<sup>+</sup> cells are in blue. Red arrows highlight cells only labelled by HLA-  
186 mismatched EBV dextramers. **f.** Chord diagram showing TCR binding to HLA-mismatched dextramers  
187 loaded with peptides from EBV. **g.** Chord diagram showing TCR binding to HLA-mismatched dextramers  
188 loaded with peptides from unrelated viruses. The full list of the different peptides is in Supplementary  
189 table 5. **h.** Correlation between the binding scores for the different HLA-mismatched virus-specific  
190 dextramers from 2 patients.

191

192 These peculiar properties led us to assess the functional relevance of the innate-like  
193 recognition of psT cells' TCRs. We first evaluated the *in vitro* cross-activation of T cells with  
194 different peptides. Human effector memory CD8<sup>+</sup> T cells (emCD8<sup>+</sup>) were purified according to  
195 their binding of CMV or EBV fluorescent dextramers; the sorted cells were then stimulated by  
196 either the peptide that was used to purify them, or by different ones, and their activation was  
197 measured by their IFN $\gamma$  production (Fig. 4a). All T cells were efficiently non-specifically activated  
198 by PMA/ionomycin. T cells that did not bind any dextramers could not be stimulated by any  
199 peptide. In contrast, dextramer-sorted cells could be activated by their cognate peptide and  
200 almost as well by the other (Fig. 4b). Thus, the binding of multiple dextramers appears  
201 functionally relevant, translating into proper psT cells activation by multiple unrelated peptides.

202 We then investigated whether we could detect the involvement of psT cells during *in vivo*  
203 immune responses. We first analysed individuals vaccinated against yellow fever (YFV) (Fig.  
204 4c)<sup>20</sup> or influenza (Flu) (Fig. 4d), identifying their TCR repertoires responding to YFV and Flu  
205 using the ALICE<sup>21</sup> and TCRNET algorithms<sup>22,23</sup>, respectively. Within these repertoires, we looked  
206 for known viral-specific TCR sequences. Besides YFV- and Flu-specific  $\beta$  and  $\alpha$  CDR3s (Fig. 4c &  
207 d), we could also detect CDR3s of psT cells, i.e. assigned to one or even multiple other viral  
208 specificities, notably for CMV and EBV. We then also analysed the TCR repertoire of T cells from  
209 bronchoalveolar lavages (BAL) from patients with COVID-19 pulmonary infections<sup>24</sup>, i.e. cells

210 responding to the local infection. We observed that many of these BAL T cells have the  
211 characteristics of psT cells: their CDR3s (i) could be detected within the clusters of psT cells  
212 responding to YFV and Flu infection (Fig. 4 c & d); (ii) they are highly connected to virus-specific  
213 sequences from databases (Fig. 4 e & f) and (iii) many harbour a TCR assigned to at least two  
214 specificities from CMV, EBV or Flu. Thus, psT cells migrate to the sites of primary antiviral  
215 immune responses.  
216



217

218 **Figure 4. In vitro activation and in vivo recruitment of psT cells.** **a.** Schematic representation  
 219 of the *in vitro* cross-activation experiment. **b.** In vitro activation of innate-like T cells. Percentage of IFN $\gamma$   
 220 producing emCD8<sup>+</sup> cells after activation with PMA/ionomycin (positive control), or CMV, EBV and OVA  
 221 peptides (mean  $\pm$  s.e.m. \* $p$ <0.05, Mann-Whitney test,) **c.** Identification of unconventional T cells  
 222 responding to yellow fever vaccination<sup>20</sup> (Patient P1 in<sup>20</sup>). The identification of  $\beta$ CDR3s significantly  
 223 recruited following yellow fever vaccination was performed using the ALICE algorithm<sup>21</sup> and  
 224 represented as LD $\leq$ 1 networks. CDR3s assigned to known specificities are coloured as indicated. **d.**



225 Identification of unconventional T cells responding to influenza vaccination. The identification of  $\alpha$  and  
226  $\beta$  CDR3 significantly recruited following influenza vaccination was performed using the TCNET  
227 algorithm<sup>22,23</sup> for one representative individual. **e.** Node degree  $\alpha$  and  $\beta$  CDR3 of TCRs from  
228 bronchoalveolar lavage (BAL) of COVID-19 patients<sup>24</sup> and from control repertoire clustered with virus-  
229 specific  $\alpha$  and  $\beta$  CDR3 from databases<sup>14–16</sup>. Each node represents a single CDR3, the colour of which  
230 represents its degree (log scale). **f.** Statistical analysis of node degree from **e.** (\*\*\*\* $p < 0.0001$ , Mann-  
231 Whitney test). **g.** Multiple viral specificities of the  $\alpha$  and  $\beta$  CDR3s from BAL of COVID-19 patients. Every  
232 combination of specificities is represented by the middle-coloured plot (same colour codes as in c & d).  
233 The occurrence of each combination is shown for  $\alpha$  (top bar plot) and  $\beta$  CDR3s (bottom bar plot).

234 Our findings have important implications for the study of the adaptive immune response  
235 in health, diseases and immunotherapies. They prompt reconsideration of the paradigm of  
236 highly diverse adaptive immune repertoires driving a highly antigen-specific antiviral immune  
237 response. The immune response may instead proceed through tinkering, as evolution does<sup>25</sup>.  
238 For life-threatening situations, the initial recruitment of frequent pleiospecific effector T cells  
239 might be more efficient and rapid than having to rely on rare cells with stringent specificity.  
240 This would be another mechanism of preparedness of the immune system, reminiscent of the  
241 role of (i) other unconventional T cells like MAIT and NKT cells<sup>4</sup>, (ii) TCR activation by bacterial  
242 superantigen<sup>26</sup> and (iii) natural antibodies specific for microbial determinants<sup>27</sup>. Our findings  
243 would also explain the overlooked observation that a very restricted repertoire of only about  
244 1,000 different TCRs arising from a single T cell progenitor was sufficient to cope with viral  
245 infections in a child with severe combined immunodeficiency<sup>28</sup>.

246 A fuzzy recognition by pleiospecific TCRs would explain the so-called “heterologous  
247 immunity”<sup>29,30</sup> in which T cell responses to one pathogen can have a major impact on the course  
248 and outcome of a subsequent infection with an unrelated pathogen<sup>31</sup>. In support of this  
249 concept, in humans, (i) there are abundant virus-specific memory-phenotype T cells in  
250 unexposed adults<sup>32</sup>, (ii) vaccination against measles provides better overall survival  
251 independently of measles infection<sup>33</sup> and (iii) CMV infection enhances immune responses to  
252 influenza<sup>31</sup>. Individuals’ histories of fuzzy immune responses may create “antigenic sins” that  
253 might be responsible for the diverse immune responses to viruses, from inapparent infection  
254 to fulminant immunopathology<sup>34–36</sup>. Interestingly, heterologous immunity has rarely been  
255 linked to B cell/antibody responses, which might thus be the mediators of more specific  
256 immune responses. In this regard, it is noteworthy that B cells have a machinery for somatic  
257 mutations of their BCRs that ultimately allows them to generate antibodies with increased  
258 affinity (specificity) for antigens. While TCR generation and BCR generation share many  
259 common mechanisms, the fact that T cells did not evolve to use this available machinery is

260 another indication that T cell recognition could have been selected to be more fuzzy than  
261 stringent. Further studies will have to evaluate the contribution of fuzzy immune responses to  
262 the efficacy but also the immunopathology of antimicrobial responses and to autoimmunity.

263 **Materials and methods:**

264

265 **Human samples:**

266 Thirteen human thymus samples were obtained from organ donors undergoing surgery  
267 (Department of Cardiac Surgery, Pitié-Salpêtrière Hospital, France) after approval by the  
268 *Agence de Biomédecine* and the *Ministry of Research*. Their age at the time of sampling ranged  
269 from 19 to 65 years old. The male-to-female sex ratio was 2.6.

270 For cross-activation experiments, six leukapheresis samples were freshly collected from healthy  
271 donors at EFS Paris Saint-Antoine-Crozatier (Etablissement Français du Sang, Paris, France)  
272 after informed consent and according to institutional guidelines. Donor selection was based on  
273 matching HLA-A2 class I allele.

274 For the influenza vaccination protocol, two unrelated healthy individuals were vaccinated with  
275 inactivated influenza vaccine (Influvac Tetra, Mylan) after written informed consent. The blood  
276 was collected with informed consent.

277

278 **Isolation of thymocytes and extraction of RNA:**

279 Single-cell suspensions were prepared from the thymus by mechanical disruption through  
280 nylon mesh (cell strainer). Single-cell suspensions from whole thymus were stained with  
281 antibodies anti-CD3 (AF700), anti-CD4 (APC), anti-CD8 (FITC). Cells were sorted by fluorescent  
282 activated cell sorting (Becton Dickinson™ FACSARIA II) with purity >95% to collect populations  
283 based on the following labelling: DPCD3<sup>-</sup> were gated as CD3<sup>-</sup>CD4<sup>+</sup>CD8<sup>+</sup>, DPCD3<sup>+</sup> were gated as  
284 CD3<sup>+</sup>CD4<sup>+</sup>CD8<sup>+</sup> and CD8<sup>+</sup> were gated as CD3<sup>+</sup>CD4<sup>-</sup>CD8<sup>+</sup>. RNA was isolated from sorted  
285 populations by means of lysis buffer with the RNAqueous-Kit (Invitrogen®) extraction kit,  
286 according to the manufacturer's protocol. The RNA concentration and sample integrity were  
287 determined on NanoDrop (Thermo Fisher®).

288

289 **TCR repertoire library preparation and sequencing**

290 T cell receptor (TCR) beta libraries were prepared on 100 ng of RNA from each sample with the  
291 SMARTer Human TCR a/b Profiling Kit (Takarabio®) following the provider's protocol. Briefly,  
292 the reverse transcription was performed using TRBC reverse primers and further extended with  
293 a template-switching oligonucleotide (SMART-Seq® v4). cDNAs were then amplified following  
294 two semi-nested PCRs: a first PCR with TRBC and TRAC reverse primers as well as a forward

295 primer hybridising to the SMART-Seqv4 sequence added by template-switching and a second  
296 PCR targeting the PCR1 amplicons with reverse and forward primers including Illumina Indexes  
297 allowing for sample barcoding. PCR2 were then purified using AMPure beads (Beckman-  
298 Coulter®). The cDNA samples were quantified and their integrity was checked using DNA  
299 electrophoresis performed on an Agilent 2100 Bioanalyzer System in combination with the  
300 Agilent DNA 1000 kit, according to the manufacturer's protocol. Sequencing was performed  
301 with Hiseq 2500 (Illumina®) SR-300 protocols using the LIGAN-PM Genomics platform (Lille,  
302 France).

303

#### 304 **TCR deep sequencing data processing**

305 FASTQ raw data files were processed for TRB sequence annotation using MiXCR<sup>37</sup> software  
306 (v2.1.10) with RNA-Seq parameters. MiXCR extracts TRBs and provides corrections of PCR and  
307 sequencing errors.

308

#### 309 **Network generation and representation**

310 To construct a network, we computed a distance matrix of pairwise Levenshtein distances  
311 between CDR3s using the "stringdist"<sup>38</sup> R package. When two sequences were similar under  
312 the defined threshold, LD>1 (i.e., at most one amino acid difference), they were connected and  
313 designated as "clustered" nodes. CDR3s with more than one amino acid difference from any  
314 other sequences are not connected and were designated as "dispersed" nodes.

315 Layout of networks for Fig. 1b and Supplementary Fig. 9a were obtained by using the graphopt  
316 algorithm of the "lgraph"<sup>39</sup> R package and plotted in 2D with "ggplot2" to generate figures<sup>40</sup>.  
317 Only clustered nodes are represented, edges are not shown and colours represent the node  
318 degree (log scale).

319 Layouts of detailed networks in Fig. 1a, Fig. 2g, Fig. 4c, Fig. 4d & Supplementary Fig. 1a,  
320 Supplementary Fig. 3 & Supplementary Fig. 12 were done with Cytoscape<sup>41</sup>.

321

#### 322 **Statistical analysis and visualisation**

323 Normalisation was performed by sampling on the top  $\alpha$  or  $\beta$  18,000 CDR3s based on their  
324 frequency in each sample. The repertoires with less than 18,000  $\alpha$  or  $\beta$  CDR3s were not  
325 included in the statistical analysis. The numbers of samples included in the statistical analysis  
326 for the  $\beta$  repertoire were: two for DPCD3<sup>-</sup>, ten for DPCD3<sup>+</sup> and twelve for CD8<sup>+</sup>. The numbers

327 of samples included in the statistical analysis of the  $\alpha$  repertoire were: six for DP3D3<sup>+</sup> and ten  
328 for CD8<sup>+</sup>. Statistical tests used to analyse data are included in the figure legends. Comparisons  
329 of two groups were done using the Mann-Whitney test (Fig. 1c, Fig. 1d, Fig. 1e, Fig. 1g, Fig. 2a,  
330 Fig. 2c, Fig. 2e Fig. 2f, Fig. 4b) and multiple t-test (Supplementary Fig. 5, Supplementary Fig. 9).  
331 The correlation coefficient was calculated using the Pearson correlation coefficient  
332 (Supplementary Fig. 4). Enrichment of public CDR3s or virus-associated CDR3s was done using  
333 the two-tailed Chi-square test with Yate's correction (Fig. 2f, Supplementary table 1, 2 & 3) and  
334 the Fisher test (Supplementary Fig. 8, Supplementary Fig. 11). Statistical comparisons and  
335 multivariate analyses were performed using Prism (GraphPad Software, La Jolla, CA) and using  
336 R software version 3.5.0 ([www.r-project.org](http://www.r-project.org)). PCA was performed on the frequency of VJ  
337 combination usage frequency within each donor using the factoextra R package. Tsnes were  
338 generated using the binding scores of each cell across all the antigens present in the dataset,  
339 disregarding the HLA matching with the donor. The function Rtsne of the homonymous R  
340 package<sup>42</sup> was applied with the perplexity parameter set to 10. Correlograms were generated  
341 using the cells that have a significant binding score (i.e. >10) for at least one of the virus-specific  
342 dextramers tested. The correlation was calculated across all the antigens present on each  
343 correlogram (Pearson test). Correlograms were plotted using the corrplot R package.

344

#### 345 **Probability of generation calculation**

346 The generation probability (Pgen) of a sequence is inferred using the Olga<sup>33</sup> algorithm, which  
347 is inferred by IGoR<sup>44</sup>, for Fig. 1e, Fig. 2c. IGoR uses out-of-frame sequence information to infer  
348 patient-dependent models of VDJ recombination, effectively bypassing selection. From these  
349 models, the probability of a given recombination scenario can be computed. The generation  
350 probability of a sequence is then obtained by summing over all the scenarios that are  
351 compatible with it. We also used OLGA to generate a random repertoire of 500,000 sequences  
352 for each  $\alpha$  or  $\beta$  repertoire and 3 down-sampling (of unique sequences) to get control repertoire  
353 equal to the size of COVID-19 BAL dataset used in fig. 4c, 4d. The control repertoire was  
354 parametrized by the predefined genomic templates provided with the package.

355

#### 356 **CDR3 connections between individuals**

357 In Supplementary Fig. 9, the top 1,500  $\beta$ CDR3s were sampled from each of the 12 datasets of  
358 DPCD3<sup>+</sup> and CD8<sup>+</sup>, then merged to obtain two datasets of 18,000  $\beta$ CDR3s for DPCD3<sup>+</sup> and CD8<sup>+</sup>.  
359 We generated and represented networks, as described above, to investigate the  $\beta$ CDR3 inter-  
360 individual network structure.

361

### 362 **Virus-specific $\beta$ CDR3 tetramer public databases**

363 The virus-associated CDR3 databases used for the search for specificity was compiled from the  
364 most complete previously published McPAS-TCR<sup>14</sup> and VDJdb<sup>15</sup> databases. Virus-associated  
365  $\beta$ CDR3s were selected from the original datasets only when derived from a TCR of sorted CD8  
366 T cells that were bound by a specific tetramer. A total of 5,437 such unique tetramer-associated  
367  $\beta$ CDR3s were identified and used. Peptides used for tetramer sorting were from  
368 cytomegalovirus (CMV), Epstein-Barr virus (EBV), hepatitis C virus (HCV), herpes simplex virus  
369 2 (HSV2), human immunodeficiency virus (HIV), influenza and yellow fever virus (YFV).

370

### 371 **Virus-specific CDR3 single-cell dextramer public dataset**

372 This dataset contains single-cell alpha/beta TCRs from 160 914 CD8<sup>+</sup> T cells isolated from  
373 peripheral blood mononuclear cells (PBMCs) from 4 healthy donors. Briefly, 30 dCODE™  
374 Dextramer® reagents (Immudex®) with antigenic peptides derived from infectious diseases (9  
375 from CMV, 12 from EBV, 1 for influenza, 1 for HTLV, 2 for HPV and 5 for HIV) were  
376 simultaneously used to mark cells. Each Dextramer® reagent included a distinct nucleic acid  
377 barcode. A panel of fluorescently labelled antibodies was used to sort pure Dextramer®-  
378 positive cells within the CD8<sup>+</sup> T cell population using an MA900 Multi-Application Cell Sorter  
379 (Sony Biotechnology) in a reaction mix containing RT Reagent Mix and Poly dT RT primers. The  
380 Chromium Single Cell V(D)J workflow generates single cell V(D)J and Dextramer® libraries from  
381 amplified DNA derived from Dextramer®-conjugated barcode oligonucleotides, which are  
382 bound to TCRs. Chromium Single Cell V(D)J enriched libraries and cell surface protein libraries  
383 were quantified, normalised, and sequenced according to the user guide for Chromium Single  
384 Cell V(D)J reagent kits with feature barcoding technology for cell surface protein. We used this  
385 dataset to study the presence of multiple specificities in TCR and CDR3. There were 139,378  
386 unambiguous TCRs (with only one  $\alpha$  and one  $\beta$  chain). We set the threshold defining positive  
387 binding at UMI counts greater than 10 for any given dextramer. This identified 15,195 unique  
388 virus-specific TCRs with at least one binding.

389

### 390 **Single-cell sequencing of TCRs from bronchoalveolar lavages from COVID-19 patients**

391 This dataset contains single-cell alpha/beta TCRs from T cells isolated from bronchoalveolar  
392 lavage (BAL) of 9 patients infected by COVID-19<sup>24</sup>. We excluded the TCRs from cells in which  
393 more than 1 CDR3aa alpha and 1 CDR3aa beta were detected.

394

### 395 **Cross-activation experiment**

396 PBMCs were separated on Ficoll gradient. CD8<sup>+</sup> T cells were isolated from PBMCs by positive  
397 isolation using the DYNABEADS<sup>®</sup> CD8 Positive Isolation Kit (Thermo Fisher Scientific) according  
398 to the manufacturer's instructions. emCD8 T cells were purified after staining with CD3-AF700,  
399 CD8-KO, CD45RA-PeCy7 according to the manufacturer's instructions. The samples were also  
400 stained either with CMV pp65 NLVPMVATV or with EBV BMLF-1 GLCTLVAML PE-conjugated  
401 Dextramers (Immudex<sup>®</sup>). emCD8<sup>+</sup>Dex<sup>+</sup> cells were sorted by FACS (FACS Aria II<sup>®</sup>; BD Biosciences)  
402 with a purity >95%. Sorted cells were cultured at a maximum of  $5 \times 10^5$  cells/mL in round-  
403 bottom 96-well plates in RPMI 1640 medium supplemented with 10% FCS, 1%  
404 penicillin/streptomycin and glutamate at 37°C with 5% CO<sub>2</sub>. *In vitro* stimulation was performed  
405 24 hours after cell sorting. Sorted cells were stimulated for 6 hours with either nothing or 1  
406 µg/mL of SIINFEKL ovalbumin peptide (OVA), NLVPMVATV cytomegalovirus pp65 peptide  
407 (CMV) or GLCTLVAML Epstein-Barr virus BMLF-1 peptide (Ozyme<sup>®</sup>). The positive control (Ctl  
408 PMA/Iono) was performed with 50 ng/mL phorbol myristate acetate (PMA) and 1 mM  
409 ionomycin. Intracellular IFN-γ production with an IFN-γ-FITC antibody (BD Pharmingen) was  
410 detected in the presence of Golgi-Plug (BD Pharmingen<sup>®</sup>) after fixation and permeabilisation  
411 (BD Cytofix/Cytoperm). Data were acquired using a Navios flow cytometer and analysed with  
412 Kaluza analysis software (Beckman Coulter).

413

### 414 **Influenza vaccination protocol**

415 Peripheral blood was obtained before vaccination and on day 14 after vaccination. PBMCs were  
416 stained with antibodies anti-CD3 (AF700), anti-CD8 (FITC), CD45RA (PeCy7), CCR7 (BV421). Cells  
417 were sorted by fluorescent activated cell sorting (Becton Dickinson<sup>™</sup> FACS Aria II) with purity  
418 >95% to collect populations based on the following labelling: naïve CD8 were gated as CD3<sup>+</sup>CD8<sup>-</sup>  
419 CD45RA<sup>+</sup>CCR7<sup>+</sup> and effector memory CD8 were gated as CD3<sup>+</sup>CD8<sup>-</sup>CD45RA<sup>-</sup>CCR7<sup>-</sup>. RNA

420 extraction, library preparation, sequencing and raw data processing were performed as  
421 described above.

422

### 423 **Identification of TCR enrichment after vaccination**

424 Homologous groups of TCRs that are specifically recruited during an antigen-specific response  
425 following yellow fever or influenza vaccination were sought using with the previously published  
426 algorithms ALICE<sup>21</sup> and TCRNET<sup>22,23</sup>, respectively. The difference between the two algorithms  
427 is that ALICE uses the VDJ rearrangement model as a control<sup>45</sup> while TCRNET uses real control  
428 samples as background.

429




- 430 1. Bradley, P. & Thomas, P. G. Using T Cell Receptor Repertoires to Understand the  
431 Principles of Adaptive Immune Recognition. *Annu. Rev. Immunol.* **37**, 547–570 (2019).
- 432 2. Qi, Q. *et al.* Diversity and clonal selection in the human T-cell repertoire. *Proc. Natl.*  
433 *Acad. Sci.* **111**, 13139–13144 (2014).
- 434 3. Nikolich-Zugich, J., Slifka, M. K. & Messaoudi, I. The many important facets of T-  
435 cell repertoire diversity. *Nat. Rev. Immunol.* **4**, 123–132 (2004).
- 436 4. Godfrey, D. I., Uldrich, A. P., McCluskey, J., Rossjohn, J. & Moody, D. B. The  
437 burgeoning family of unconventional T cells. *Nat. Immunol.* **16**, 1114–1123 (2015).
- 438 5. Rossjohn, J. *et al.* T Cell Antigen Receptor Recognition of Antigen-Presenting  
439 Molecules. *Annu. Rev. Immunol.* **33**, 169–200 (2015).
- 440 6. Dash, P. *et al.* Quantifiable predictive features define epitope-specific T cell receptor  
441 repertoires. *Nature* **547**, 89–93 (2017).
- 442 7. Klinger, M. *et al.* Multiplex Identification of Antigen-Specific T Cell Receptors Using  
443 a Combination of Immune Assays and Immune Receptor Sequencing. *PLOS ONE* **10**,  
444 e0141561 (2015).
- 445 8. Madi, A. *et al.* T cell receptor repertoires of mice and humans are clustered in  
446 similarity networks around conserved public CDR3 sequences. *eLife* **6**, (2017).
- 447 9. Chen, G. *et al.* Sequence and Structural Analyses Reveal Distinct and Highly Diverse  
448 Human CD8 + TCR Repertoires to Immunodominant Viral Antigens. *Cell Rep.* **19**, 569–583  
449 (2017).
- 450 10. Glanville, J. *et al.* Identifying specificity groups in the T cell receptor repertoire.  
451 *Nature* **547**, 94–98 (2017).
- 452 11. Qi, Q. *et al.* Diversification of the antigen-specific T cell receptor repertoire after  
453 varicella zoster vaccination. *Sci. Transl. Med.* **8**, 332ra46–332ra46 (2016).
- 454 12. Meysman, P. *et al.* On the viability of unsupervised T-cell receptor sequence  
455 clustering for epitope preference. *Bioinformatics* **35**, 1461–1468 (2019).
- 456 13. Thomas, P. G. & Crawford, J. C. Selected before selection: A case for inherent antigen  
457 bias in the T-cell receptor repertoire. *Curr. Opin. Syst. Biol.* **18**, 36–43 (2019).
- 458 14. Tickotsky, N., Sagiv, T., Prilusky, J., Shifrut, E. & Friedman, N. McPAS-TCR: a  
459 manually curated catalogue of pathology-associated T cell receptor sequences. *Bioinformatics*  
460 **33**, 2924–2929 (2017).
- 461 15. Shugay, M. *et al.* VDJdb: a curated database of T-cell receptor sequences with known  
462 antigen specificity. *Nucleic Acids Res.* **46**, D419–D427 (2018).
- 463 16. 10x\_AN047\_IP\_A\_New\_Way\_of\_Exploring\_Immunity\_Digital (1).pdf.
- 464 17. Nelson, R. W. *et al.* T Cell Receptor Cross-Reactivity between Similar Foreign and  
465 Self Peptides Influences Naive Cell Population Size and Autoimmunity. *Immunity* **42**, 95–107  
466 (2015).
- 467 18. Toubal, A., Nel, I., Lotersztajn, S. & Lehuen, A. Mucosal-associated invariant T cells  
468 and disease. *Nat. Rev. Immunol.* **19**, 643–657 (2019).
- 469 19. Mori, L., Lepore, M. & De Libero, G. The Immunology of CD1- and MR1-Restricted  
470 T Cells. *Annu. Rev. Immunol.* **34**, 479–510 (2016).
- 471 20. Pogorelyy, M. V. *et al.* Precise tracking of vaccine-responding T cell clones reveals  
472 convergent and personalized response in identical twins. *Proc. Natl. Acad. Sci. U. S. A.* **115**,  
473 12704–12709 (2018).
- 474 21. Pogorelyy, M. V. *et al.* Detecting T cell receptors involved in immune responses from  
475 single repertoire snapshots. *PLOS Biol.* **17**, e3000314 (2019).
- 476 22. Shugay, M. *et al.* VDJtools: Unifying Post-analysis of T Cell Receptor Repertoires.  
477 *PLOS Comput. Biol.* **11**, e1004503 (2015).
- 478 23. Ritvo, P.-G. *et al.* High-resolution repertoire analysis reveals a major bystander  
479 activation of Tfh and Tfr cells. *Proc. Natl. Acad. Sci.* **115**, 9604–9609 (2018).


- 480 24. Liao, M. *et al.* Single-cell landscape of bronchoalveolar immune cells in patients with  
481 COVID-19. *Nat. Med.* (2020) doi:10.1038/s41591-020-0901-9.
- 482 25. Jacob, F. (1977). Evolution and tinkering. *Science*, 196(4295), 1161-1166.
- 483 26. Hayday, A. C. & Vantourout, P. The Innate Biologies of Adaptive Antigen Receptors.  
484 *Annu. Rev. Immunol.* **38**, annurev-immunol-102819-023144 (2020).
- 485 27. Panda, S. & Ding, J. L. Natural Antibodies Bridge Innate and Adaptive Immunity. *J.*  
486 *Immunol.* **194**, 13–20 (2015).
- 487 28. Bousoo, P. *et al.* Diversity, functionality, and stability of the T cell repertoire derived  
488 in vivo from a single human T cell precursor. *Proc. Natl. Acad. Sci.* **97**, 274–278 (2000).
- 489 29. Welsh, R. M. & Selin, L. K. No one is naive: the significance of heterologous T-cell  
490 immunity. *Nat. Rev. Immunol.* **2**, 417–426 (2002).
- 491 30. Sewell, A. K. Why must T cells be cross-reactive? *Nat. Rev. Immunol.* **12**, 669–677  
492 (2012).
- 493 31. Furman, D. *et al.* Cytomegalovirus infection enhances the immune response to  
494 influenza. *Sci. Transl. Med.* **7**, 281ra43-281ra43 (2015).
- 495 32. Su, L. F., Kidd, B. A., Han, A., Kotzin, J. J. & Davis, M. M. Virus-Specific CD4+  
496 Memory-Phenotype T Cells Are Abundant in Unexposed Adults. *Immunity* **38**, 373–383  
497 (2013).
- 498 33. Aaby, P. *et al.* Non-specific effects of standard measles vaccine at 4.5 and 9 months of  
499 age on childhood mortality: randomised controlled trial. *BMJ* **341**, c6495–c6495 (2010).
- 500 34. Peteranderl, C., Herold, S. & Schmoldt, C. Human Influenza Virus Infections. *Semin.*  
501 *Respir. Crit. Care Med.* **37**, 487–500 (2016).
- 502 35. Bertoletti, A. & Ferrari, C. Adaptive immunity in HBV infection. *J. Hepatol.* **64**, S71–  
503 S83 (2016).
- 504 36. Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of  
505 COVID-19: immunity, inflammation and intervention. *Nat. Rev. Immunol.* (2020)  
506 doi:10.1038/s41577-020-0311-8.
- 507 37. Bolotin, D. A. *et al.* MiXCR: software for comprehensive adaptive immunity  
508 profiling. *Nat. Methods* **12**, 380–381 (2015).
- 509 38. van der Loo, M. P. J. The stringdist package for approximate string matching. *The R*  
510 *Journal*, 6(1), 111-122.
- 511 39. Csardi, G. & Nepusz, T. The igraph software package for complex network research.  
512 40. Wickham, H. *ggplot2: elegant graphics for data analysis.* (Springer, 2016).
- 513 41. Shannon, P. Cytoscape: A Software Environment for Integrated Models of  
514 Biomolecular Interaction Networks. *Genome Res.* **13**, 2498–2504 (2003).
- 515 42. Krijthe, J. H. Rtsne: T-distributed stochastic neighbor embedding using Barnes-Hut  
516 implementation. *R Package Version 013 URL [Httpsgithub ComjkrijtheRtsne](https://github.com/jkrijthe/Rtsne)* (2015).
- 517 43. Sethna, Z., Elhanati, Y., Jr, C. G. C. & Mora, T. OLGA: fast computation of  
518 generation probabilities of B- and T-cell receptor amino acid sequences and motifs. 8.
- 519 44. Marcou, Q., Mora, T. & Walczak, A. M. High-throughput immune repertoire analysis  
520 with IGoR. *Nat. Commun.* **9**, (2018).
- 521 45. Murugan, A., Mora, T., Walczak, A. M. & Callan, C. G. Statistical inference of the  
522 generation probability of T-cell receptors from sequence repertoires. *Proc. Natl. Acad. Sci.*  
523 **109**, 16161–16166 (2012).
- 524

525 SUPPLEMENTARY MATERIALS  
526  
527

a




528  
529 **Supplementary Figure 1. TCRs with the same specificity form clusters. a.** Networks of  $\beta$ CDR3s  
530 specific for GILGFVFTL from influenza (orange), GLCTLVAML from Epstein-Barr virus (green) and  
531 FPRPWLHGL from human immunodeficiency virus (blue) are shown. These  $\beta$ CDR3s are from  
532 TCRs identified on CD8 T lymphocytes isolated with class I tetramer<sup>14,15</sup> loaded with the  
533 indicated peptides<sup>14,15</sup>. Each node represents a clonotype. Two different clonotypes are  
534 connected if their  $\beta$ CDR3s differ by at most one amino acid ( $LD \leq 1$ ).



535  
536  
537  
538  
539  
540

**Supplementary Figure 2. Clustered  $\alpha$ CDR3s from DPCD3<sup>+</sup> and CD8<sup>+</sup> thymocytes.** Analyses were performed on the first 18,000 most frequent  $\alpha$ CDR3s per sample (n=6 for DPCD3<sup>+</sup> and n=10 for CD8<sup>+</sup> thymocytes). **a.** Percentage of clustered  $\alpha$ CDR3s. (mean $\pm$ s.e.m., \*p=0.016, Mann-Whitney test). **b.** Degree of clustered  $\alpha$ CDR3s. (mean $\pm$ s.e.m., \*\*\*\*p<0.0001, Mann-Whitney test).


541




542  
543  
544  
545

**Supplementary Figure 3.  $\beta$ CDR3 network during thymopoiesis.** Representation of the 18,000 most frequent  $\beta$ CDR3 networks from DPCD3<sup>+</sup> and CD8<sup>+</sup> thymocytes of eight donors (Pn).






**Supplementary Figure 4. Correlation between  $P_{gen}$  and  $\beta$ CDR3 number of connections in the  $CD8^+$  thymocyte repertoire.** The contour plots represent the generation probability as a function of  $\beta$ CDR3 connections in the  $CD8^+$  thymocytes for donors P11 to P36. Linear regression curves between  $P_{gen}$  and number of connections are represented as red dashed lines (“y” represents the regression curve’s equation). The Pearson correlation coefficient “R” and p-value “p” are calculated for each individual.




553  
 554 **Supplementary Figure 5. Clonogram representation of TCR Vβ and Jβ usage in clustered versus**  
 555 **dispersed CD8<sup>+</sup> thymocytes.** The bar plots represent the mean percentage of TCR Vβ (up) and  
 556 Jβ (down) in dispersed (light grey) versus clustered (dark grey). (\* p<0.01, multiple t-test).

## DPCD3<sup>+</sup>




## CD8<sup>+</sup>



557  
558  
559  
560  
561

**Supplementary Figure 6.  $\beta$ CDR3 sharing between individuals.** Pie charts represent the sharing between individuals before (DPCD3<sup>+</sup>) and after thymic selection (CD8<sup>+</sup>). Colours represent the dispersed (grey) or clustered (blue) CDR3s. Sharing was analyzed within the 10 donors for which there were at least 18,000  $\beta$ CDR3s in DPCD3<sup>+</sup> and in CD8<sup>+</sup> thymocytes.






562

563 **Supplementary Figure 7. The number of public  $\beta$ CDR3s in CD8<sup>+</sup> thymocytes is independent of**  
564 **the number of HLA-I alleles shared.** Each dot represents the number of  $\beta$ CDR3s shared between  
565 two donors in the first 18,000 CD8<sup>+</sup> thymocytes. There is no significant difference in the number  
566 of public  $\beta$ CDR3s according to the number of HLA-I alleles shared. The number of public  $\beta$ CDR3s  
567 is independent of the number of HLA alleles shared.

568

569




570

571 **Supplementary Figure 8. Enrichment of public  $\beta$ CDR3s in the CD8<sup>+</sup> thymocyte repertoires.**

572 Representation of the generation probability as a function of  $\beta$ CDR3 connections in individuals  
573 (P<sub>n</sub>). The contour plots represent shared (blue) or private (grey)  $\beta$ CDR3s. The Pearson  
574 correlation coefficient “R” and p-value “p” are calculated for each group. The black dotted lines  
575 delimit the threshold for the 2.5% sequences with the higher *P*<sub>gen</sub> and connection.  $\beta$ CDR3s  
576 with both the highest *P*<sub>gen</sub> and connections are also the most public for 12 out of 12 individuals  
577 ( $p < 0.0001$ , two-tailed Fisher test).

578



579

580 **Supplementary Figure 9. Convergence of public  $\beta$ CDR3 specificities during thymopoiesis. a.**

581 CDR3 connections between individuals. The top 1,500  $\beta$ CDR3s were sampled from DPCD3<sup>+</sup> (left)

582 and CD8<sup>+</sup> (right) cells from each individual and pooled. The CDR3s are clustered based on  $LD \leq$

583 1 with colour and size both representing the level of sharing between individuals for each CDR3.

584 **b.** Bar plots representing the percentage of CDR3s from an individual that are connected to


585 CDR3s of other individuals, for DPCD3<sup>+</sup> and CD8<sup>+</sup> thymocytes. The first two bars represent

586 CDR3s that are not connected ( $n=1$ ). The number of unconnected nodes in DPCD3<sup>+</sup> is higher

587 than in CD8<sup>+</sup> (\* $p=0.002$ ). The other bars represent the percentage of CDR3s connected

588 between individuals. The number of nodes connected to 3 to 10 individuals is significantly


589 higher in CD8<sup>+</sup> than in DPCD3<sup>+</sup> cells (\* $p < 0.01$ , multiple t-test).



590  
591

592 **Supplementary Figure 10. Virus-specific CDR3s among DPCD3<sup>+</sup> and CD8<sup>+</sup> thymocytes.** Bar plots  
593 represent the percentage, within the top 18,000  $\beta$ CDR3s of each donors, of  $\beta$ CDR3s from TCRs  
594 identified as virus-specific based on tetramer identification<sup>14,15</sup>. For each panel, the percentage  
595 is calculated within dispersed (left boxplot) or clustered (right boxplot)  $\beta$ CDR3s. Colours  
596 correspond to different viral specificities.



597



598

599 **Supplementary Figure 11. Enrichment of virus-specific  $\beta$ CDR3s in the CD8<sup>+</sup> thymocyte**  
600 **repertoire.** Representation of the generation probability as a function of  $\beta$ CDR3 connections in  
601 individuals (Pn). The contour plots represent  $\beta$ CDR3s from TCRs identified as virus-specific  
602 based on tetramer identification<sup>14,15</sup> (red) or with unknown specificity (grey). The Pearson  
603 correlation coefficient “R” and p-value “p” are calculated for each group. The black dotted lines  
604 delimit the threshold for the 2.5% sequences with both higher  $P_{gen}$  and degree of connection.  
605  $\beta$ CDR3s with both the highest  $P_{gen}$  and connections were also the most virus-specific for 11  
606 out of 12 individuals (p-value <0.0001, two-tailed Fisher test).


607



608

609 **Supplementary Figure 12. Single clusters of  $\beta$ CDR3s from CD8<sup>+</sup> thymocytes comprise TCRs with**  
610 **different viral specificities.** The tagged dots represent  $\beta$ CDR3s with known specificity according  
611 to the public database<sup>14,15</sup>.  $\beta$ CDR3 specific for unrelated virus epitopes can be found close to  
612 or even directly linked in the cluster.

613



614  
615

616 **Supplementary Figure 13. TSNE representation of the single-cell EBV and CMV TCR specificities**  
617 **from one seronegative individual.** CD8<sup>+</sup> T cells are able to bind both EBV and CMV HLA-matched  
618 dextramers. EBV Dex<sup>+</sup>-specific cells are in blue and CMV Dex<sup>+</sup>-specific cells are in green. Some  
619 of the cells are specific for both.

620

		DP	CD8	p-value	Odds ratio
P11	Public	590	1630	p<0.0001	0.3403
	Private	17410	16370		
P18	Public	695	1567	p<0.0001	0.4212
	Private	17305	16433		
P19	Public	485	1489	p<0.0001	0.3071
	Private	17515	16511		
P23	Public	649	1489	p<0.0001	0.4148
	Private	17351	16511		
P24	Public	578	1416	p<0.0001	0.3886
	Private	17422	16584		
P25	Public	640	1536	p<0.0001	0.3952
	Private	17360	16464		
P26	Public	584	1470	p<0.0001	0.3771
	Private	17416	16530		
P27	Public	640	1583	p<0.0001	0.3823
	Private	17360	16417		
P29	Public	655	1583	p<0.0001	0.3916
	Private	17345	16417		
P36	Public	653	1468	p<0.0001	0.4239
	Private	17347	16532		

621  
622 **Supplementary table 1. Enrichment of public  $\beta$ CDR3s in CD8<sup>+</sup> thymocytes vs DPCD3<sup>+</sup>.**  
623 Contingency table for the Chi-square analysis performed with Yates' correction to test the null  
624 hypothesis of independence between the sharing of  $\beta$ CDR3s (Public or Private) vs the cell  
625 phenotype (DPCD3<sup>+</sup> and CD8<sup>+</sup>). We performed this test in the 10 donors for which we have  
626 18,000  $\beta$ CDR3s in both DPCD3<sup>+</sup> and CD8<sup>+</sup> thymocytes. A  $\beta$ CDR3 is defined as public if it is found  
627 at least once in the 18,000  $\beta$ CDR3s of the same cell phenotype from other donors. The results  
628 (p-value < 0.0001) rejected the null hypothesis, thereby indicating the interdependency of the  
629 two variables.  
630  
631



		Clustered	Dispersed	p-value	Odds ratio
P11	Virus Tet+	106	8	p<0.0001	40.75
	Unknown	4389	13497		
P18	Virus Tet+	126	10	p<0.0001	39.93
	Unknown	4285	13579		
P19	Virus Tet+	102	8	p<0.0001	46.77
	Unknown	3832	14058		
P23	Virus Tet+	93	7	p<0.0001	47.82
	Unknown	3892	14008		
P24	Virus Tet+	96	9	p<0.0001	40.38
	Unknown	3739	14156		
P25	Virus Tet+	112	7	p<0.0001	63.60
	Unknown	3594	14287		
P26	Virus Tet+	83	2	p<0.0001	146.1
	Unknown	3963	13952		
P27	Virus Tet+	99	8	p<0.0001	34.60
	Unknown	4714	13179		
P29	Virus Tet+	55	9	p<0.0001	31.65
	Unknown	2903	15033		
P31	Virus Tet+	104	1	p<0.0001	360.8
	Unknown	4004	13891		
P32	Virus Tet+	44	9	p<0.0001	32.93
	Unknown	2320	15627		
P36	Virus Tet+	86	6	p<0.0001	54.12
	Unknown	3750	14158		

632  
633  
634  
635  
636  
637  
638  
639

**Supplementary table 2. Enrichment of virus-specific  $\beta$ CDR3s from databases<sup>14,15</sup> in clustered CD8<sup>+</sup> thymocytes.** Contingency table for the Chi-square analysis performed with Yates' correction to test the null hypothesis of independence between the specificity of  $\beta$ CDR3s (Virus Tet<sup>+</sup> and Unknown specificities) vs the connection of  $\beta$ CDR3 ("clustered" and "dispersed") in all the CD8<sup>+</sup> thymocytes from 12 donors. The results (p-value < 0.0001) rejected the null hypothesis, thereby indicating the interdependency of the two variables.

		Clustered	Dispersed	p-value	Odds ratio
P11	Virus Dex+	223	22	p<0.0001	31.99
	Unknown	4272	13483		
P18	Virus Dex+	225	26	p<0.0001	28.04
	Unknown	4186	13563		
P19	Virus Dex+	200	25	p<0.0001	30.08
	Unknown	3734	14041		
P23	Virus Dex+	211	19	p<0.0001	41.18
	Unknown	3774	13996		
P24	Virus Dex+	194	25	p<0.0001	30.14
	Unknown	3641	14140		
P25	Virus Dex+	264	11	p<0.0001	99.59
	Unknown	3442	14283		
P26	Virus Dex+	216	18	p<0.0001	43.66
	Unknown	3830	13936		
P27	Virus Dex+	220	20	p<0.0001	31.53
	Unknown	4593	13167		
P29	Virus Dex+	143	22	p<0.0001	34.68
	Unknown	2815	15020		
P31	Virus Dex+	200	23	p<0.0001	30.86
	Unknown	3908	13869		
P32	Virus Dex+	102	20	p<0.0001	35.21
	Unknown	2262	15616		
P36	Virus Dex+	187	25	p<0.0001	28.98
	Unknown	3649	14139		

640  
641  
642  
643  
644  
645  
646  
647  
648

**Supplementary table 3. Enrichment of virus-specific  $\beta$ CDR3s from the single-cell sequencing dataset<sup>16</sup> in clustered CD8<sup>+</sup> thymocytes.** Contingency table for the Chi-square analysis performed with the Yates correction to test the null hypothesis of independence between the specificity of  $\beta$ CDR3s (Virus Dex<sup>+</sup> and Unknown specificity) vs the connection of  $\beta$ CDR3s (“clustered” and “dispersed”) in all CD8<sup>+</sup> thymocytes from 12 donors. The results (p-value < 0.0001) rejected the null hypothesis, thereby indicating the interdependency of the two variables.

649

Peptide	Virus
FLRGRAYGL	EBV
FLYALALLL	EBV
GLCTLVAML	EBV
LLDFVRFMGV	EBV
RAKFKQLL	EBV
RTLNAWVKV	HIV
SLFNTVATL	HIV
SLFNTVATLY	HIV
MLDLQPETT	HPV
LLFGYPVYV	HTLV
GILGFVFTL	Influenza
ELRRKMMYM	CMV
VTEHDTLLY	CMV
SLYNTVATLY	HIV

650 **Supplementary table 4.** List of peptides represented in the chord plot of Fig 3c. The table is  
651 organized according to the clockwise order of the chord plot segments.

652

Peptide	Virus
KLGGALQAK	CMV
QYDPVAALF	CMV
RIPHERNGFTVL	CMV
TPRVTGGGAM	CMV
AVFDRKSDAK	EBV
IVTDFSVIK	EBV
QPRAPIRPI	EBV
RLRAEAQVK	EBV
RPPIFIRRL	EBV
AYAQQIFKI	CMV
IPSINVHHY	CMV

653 **Supplementary table 5. List of peptides represented in the chord plot of Fig 3g.** The table is  
654 organized according to the clockwise order of the chord plot segments.

655

656

657

## 658 Acknowledgements

659 The authors would like to express their gratitude to the donors and their families who allowed  
660 the collection of samples for research under sad circumstances. The authors would also like to  
661 thank Prof. Pascal Leprince, Dr. Guillaume Lebreton, and Dr. Marina Rigolet of the cardiac  
662 surgery team, and Prof. Bruno Riou and the graft coordination team, of the Pitié-Salpêtrière  
663 hospital for their contribution to sample collection. The authors thank the UMR 8199 LIGAN-  
664 PM Genomics platform (Lille, France) for sequencing. We thank Thierry Mora and Aleksandra  
665 Walczak of the Ecole Normale Supérieure de Paris for helpful discussion.

666

## 667 Author contributions

668 VQ performed the experiments with assistance from PB, HV and EMF; VQ, PB, VM and HPP  
669 analysed data with contributions from all authors; VQ and DK wrote the manuscript; DK  
670 conceptualized and supervised the study.

671

## 672 Data availability statement

673 Datasets from VDJdb were downloaded from <https://vdjdb.cdr3.net>. Datasets from McPAS-TCR  
674 were downloaded from <http://friedmanlab.weizmann.ac.il/McPAS-TCR/>. We manually curated  
675 these datasets to be sure to use only  $\beta$ CDR3s from CD8 tetramer-specific cells. Single-cell  
676 datasets from 10X genomics were downloaded from [https://support.10xgenomics.com/single-](https://support.10xgenomics.com/single-cell-vdj/datasets)  
677 [cell-vdj/datasets](https://support.10xgenomics.com/single-cell-vdj/datasets) ('Application Note - A New Way of Exploring Immunity' section, datasets 'CD8+  
678 T cells of Healthy Donor' 1–4, available under the Creative Commons Attribution license).  
679 Single-cell dataset of COVID-19 patient were downloaded from [https://www-ncbi-nlm-nih-](https://www-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/geo/query/acc.cgi?acc=GSE145926)  
680 [gov.proxy.insermbiblio.inist.fr/geo/query/acc.cgi?acc=GSE145926](https://www-ncbi-nlm-nih-gov.proxy.insermbiblio.inist.fr/geo/query/acc.cgi?acc=GSE145926).

681 Dataset repertoires of immunisation with live yellow fever vaccine are available in the NCBI  
682 Sequence Read Archive (accession no. PRJNA493983). Only P1 and S1 at day 15 post-  
683 vaccination are used and represented.

684 Data from the donors are available on request to the authors.

685

## 686 Competing interests

687 The authors declare no competing financial interests.

688

## 689 Funding

690 This work was primarily funded by the TRiPoD ERC-Advanced EU (322856) grant to DK, and by  
691 the LabEx Transimmunom (ANR-11-IDEX-0004-02) and RHU iMAP (ANR-16-RHUS-0001) grants.

692 **Corresponding author**

693 Correspondence to Prof. David Klatzmann

694 Immunology-Immunopathology-Immunotherapy Laboratory (i3) and Clinical Investigation  
695 Center for Biotherapies (CIC-BTi)

696 Pitié-Salpêtrière Hospital, 83 boulevard de l'Hôpital, F-75013, Paris, France.

697 E-mail: david.klatzmann@sorbonne-universite.fr